Jazz Pharmaceuticals (NASDAQ:JAZZ) Rating Reiterated by Wells Fargo & Co

Wells Fargo & Co reaffirmed their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a research report released on Wednesday morning, AnalystRatings.com reports.

JAZZ has been the subject of several other research reports. HC Wainwright reiterated a hold rating and issued a $147.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, August 8th. BMO Capital Markets set a $208.00 target price on Jazz Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, July 3rd. Oppenheimer set a $176.00 target price on Jazz Pharmaceuticals and gave the company a buy rating in a research note on Monday, July 8th. Mizuho set a $148.00 target price on Jazz Pharmaceuticals and gave the company a hold rating in a research note on Wednesday, July 3rd. Finally, Zacks Investment Research cut Jazz Pharmaceuticals from a buy rating to a hold rating in a research note on Monday, May 6th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and eleven have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $174.14.

NASDAQ JAZZ opened at $134.83 on Wednesday. Jazz Pharmaceuticals has a fifty-two week low of $113.52 and a fifty-two week high of $176.73. The company has a debt-to-equity ratio of 0.58, a quick ratio of 3.52 and a current ratio of 3.71. The stock has a 50 day simple moving average of $138.13 and a two-hundred day simple moving average of $134.53. The stock has a market cap of $7.44 billion, a P/E ratio of 9.79, a price-to-earnings-growth ratio of 1.08 and a beta of 1.14.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.16 by $0.49. Jazz Pharmaceuticals had a return on equity of 27.72% and a net margin of 32.99%. The business had revenue of $534.13 million during the quarter, compared to analysts’ expectations of $507.23 million. During the same quarter last year, the business posted $3.49 EPS. The business’s revenue was up 6.7% on a year-over-year basis. Sell-side analysts predict that Jazz Pharmaceuticals will post 13.44 earnings per share for the current year.

In related news, SVP Paul Treacy sold 4,371 shares of Jazz Pharmaceuticals stock in a transaction on Monday, August 12th. The stock was sold at an average price of $137.40, for a total value of $600,575.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Catherine A. Sohn sold 726 shares of Jazz Pharmaceuticals stock in a transaction on Friday, August 9th. The stock was sold at an average price of $135.65, for a total value of $98,481.90. Following the completion of the sale, the director now directly owns 9,574 shares of the company’s stock, valued at approximately $1,298,713.10. The disclosure for this sale can be found here. 4.30% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently modified their holdings of JAZZ. Nuveen Asset Management LLC grew its holdings in shares of Jazz Pharmaceuticals by 4,979.1% in the second quarter. Nuveen Asset Management LLC now owns 1,924,270 shares of the specialty pharmaceutical company’s stock worth $274,324,000 after acquiring an additional 1,886,384 shares during the period. Renaissance Technologies LLC grew its holdings in shares of Jazz Pharmaceuticals by 28.2% in the second quarter. Renaissance Technologies LLC now owns 2,555,801 shares of the specialty pharmaceutical company’s stock worth $364,355,000 after acquiring an additional 562,700 shares during the period. AQR Capital Management LLC grew its holdings in shares of Jazz Pharmaceuticals by 46.9% in the second quarter. AQR Capital Management LLC now owns 1,057,019 shares of the specialty pharmaceutical company’s stock worth $147,496,000 after acquiring an additional 337,396 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Jazz Pharmaceuticals by 16.7% in the first quarter. JPMorgan Chase & Co. now owns 2,262,159 shares of the specialty pharmaceutical company’s stock worth $323,376,000 after acquiring an additional 324,080 shares during the period. Finally, Wedge Capital Management L L P NC bought a new stake in shares of Jazz Pharmaceuticals in the first quarter worth $40,947,000. 89.59% of the stock is owned by institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Featured Article: What is an investor looking for in an SEC filing?

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.